Skip to main content
Lupin developing 7 biosimilars
1/12/2018

Indian drugmaker Lupin announced it aims to seek approval in 2019 for the biosimilar etanercept, which references Amgen's Enbrel. Other early-stage biosimilars in the company's pipeline include ranibizumab, pegfilgrastim, filgrastim, denosumab, pertuzumab and afliberept.

Full Story: